17 January 2024 in Research and Practice in Thrombosis and Haemostasis
Acquired hemophilia A (AHA) is a rare hemorrhagic disorder caused by factor (F)VIII inhibitors. The diagnosis and management of AHA remains challenging because of its rarity and heterogeneity. To analyze the characteristics of AHA to enhance our understanding of this disease and identify effective treatment strategies. To analyze the characteristics of AHA to enhance our understanding of this disease and identify effective treatment strategies. Clinical features of 165 patients with AHA from a single center between July 1997 and December 2021 were retrospectively analyzed. The median age of patients at diagnosis was 45 years. The median time to diagnosis was 30 days. All 165 patients experienced bleeding, with a median bleeding score (BS) of 4 (range, 2-12). Hemostatic therapy was administered to 129 (78.2%) patients. Bleeding control was achieved in 80.0% of patients who received prothrombin complex concentrate and in 92.3% of patients who were treated with recombinant activated FVII. Of the 163 patients who received immunosuppressive therapy, 80 (49.1%) received rituximab-based therapy with a 93.3% complete remission (CR) rate, 50 (30.7%) received steroids plus cyclophosphamide with an 85.0% CR rate, and 22 (13.5%) received steroids alone with an 82.4% CR rate. Six cases relapsed after a median duration of 330 days. Immunosuppressive therapy–related adverse events were reported in 17 patients. Seven deaths were recorded. FVIII inhibitor titer of ≥15 BU/mL and BS of ≥6 were identified as significantly poor prognostic factors for CR. Immunosuppressive therapies yield remarkably high response rates, with a CR rate exceeding 80%; notably, the regimen containing rituximab exhibits a CR rate of approximately 90%. FVIII inhibitor titer of ≥5 BU/mL and BS of ≥6 were poor predictors of CR in patients with AHA.
23 August 2024 in Research and Practice in Thrombosis and Haemostasis
Isolated acquired clotting factor deficiencies (ACFDs) are mainly caused by the existence of anti-factor antibodies or adsorption of clotting factors onto substances such as amyloid. Besides acquired factor (F)VIII deficiency (acquired hemophilia A), the remaining factor deficiencies are rare and diverse, posing challenges in both diagnosis and management. To describe different features of isolated ACFDs to improve our understanding of these diseases and provide practical recommendations for their management. Clinical characteristics of patients with isolated acquired FII, FV, FIX, FX, FXI, FXII, FXIII, and von Willebrand factor deficiencies were collected from a single center between July 1997 and December 2021 and analyzed retrospectively. A total of 54 rare isolated ACFD patients were enrolled in our study, mainly including 20 acquired FV deficiency patients and 16 acquired FX deficiency patients. The median age at diagnosis of all rare isolated ACFD patients was 55 years. The median time to diagnose all rare isolated ACFD patients was 60 days. Ten (18.5%) rare isolated ACFD patients had no bleeding and 2 (3.7%) rare isolated ACFD patients showed venous thromboembolism. Hemostatic treatment was applied to 41 (41/54; 75.9%) rare isolated ACFD patients. Thirty-seven (68.5%) rare isolated ACFD patients received immunosuppressive therapy, and 10 (18.5%) rare isolated ACFD patients received chemotherapy targeting primary diseases. Twenty-two (61.9%) rare isolated ACFD patients achieved complete remission, and 9 (21.4%) rare isolated ACFD patients died. Rare isolated ACFDs are underestimated, associated with delayed diagnosis, and lack effective therapy. Clinicians should raise awareness for recognizing and managing rare isolated ACFD patients to avoid morbidity and mortality.
15 November 2023 in British Journal of Haematology
23 July 2025 in Research Square
Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) are phenotypically similar but biologically distinct myeloproliferative neoplasms (MPNs), making accurate diagnosis critical yet challenging. We conducted a retrospective study, including 434 ET and 91 pre-PMF patients. Clinical predictors were evaluated using logistic regression in 440 patients. A subset of 85 patients underwent data-independent acquisition (DIA)–based proteomic profiling of FFPE bone marrow samples. Diagnostic models were developed using clinical, proteomic, and combined features, with performance assessed via nested cross-validation. A 9-protein classifier was constructed using random forest followed by support vector machine–recursive feature elimination (SVM-RFE). The proteomic model achieved superior diagnostic performance compared to the clinical model (AUC = 0.849 vs. 0.499) and was comparable to the combined model (AUC = 0.845). The 9-protein panel showed robust discrimination (AUC = 0.895), with top proteins (ARHGEF19, CAST, SFTPA2) performing well in JAK2V617F⁺ (AUC = 0.971) and CALR⁺ (AUC = 0.768) subsets. Proteomic profiling thus outperforms conventional clinical variables and offers a reproducible, molecular-based tool for distinguishing ET from pre-PMF, with potential utility across molecular subtypes in early-phase MPN diagnosis.